Liquid Biopsy Testing Services: ctDNA, CTC, and Extracellular Vesicle Analysis for Precision Oncolog

Liquid biopsy testing services provide minimally invasive molecular diagnostics by analyzing circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles from a simple blood draw or other body fluids. These services support cancer screening, companion diagnostics, treatment response monitoring, and minimal residual disease (MRD) detection with fast turnaround times and high analytical sensitivity. Accredited third-party laboratories deliver liquid biopsy results validated under ISO 15189 and ISO/IEC 17025 quality systems, enabling clinicians to make evidence-based precision oncology decisions.

Liquid biopsy testing services provide minimally invasive molecular diagnostics by analyzing circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles from a simple blood draw or other body fluids. These services support cancer screening, companion diagnostics, treatment response monitoring, and minimal residual disease (MRD) detection with fast turnaround times and high analytical sensitivity. Accredited third-party laboratories deliver liquid biopsy results validated under ISO 15189 and ISO/IEC 17025 quality systems, enabling clinicians to make evidence-based precision oncology decisions.

Technical Overview

Liquid biopsy is a minimally invasive diagnostic technology that detects and analyzes tumor-derived and other disease-associated biomarkers released into bodily fluids. Unlike conventional tissue biopsy, which requires a surgical or needle procedure, liquid biopsy typically requires only a peripheral blood draw, making it suitable for repeated sampling and longitudinal disease monitoring. The core analytes include circulating tumor DNA (ctDNA), circulating cell-free DNA (cfDNA), circulating tumor cells (CTCs), extracellular vesicles (exosomes), microRNAs (miRNAs), and circulating proteins.

Professional liquid biopsy testing services combine advanced sample stabilization, high-sensitivity molecular workflows, and bioinformatics pipelines to deliver clinically actionable results. Because tumor material is shed into the bloodstream from multiple lesions, liquid biopsy can capture spatial and temporal tumor heterogeneity more comprehensively than a single tissue core. Analytical performance is governed by standardized quality frameworks such as ISO 15189 for medical laboratories, ISO/IEC 17025 for testing laboratories, and CLSI molecular diagnostics guidelines.

Testing Samples

Peripheral Blood (Whole Blood)

Peripheral blood collected in specialized cell-stabilizing tubes or EDTA tubes is the most common sample type. Stabilizing tubes preserve CTC integrity and prevent genomic DNA leakage from leukocytes during transport, while EDTA tubes require plasma separation within 2-4 hours of collection. Typical draw volumes range from 10 mL to 20 mL depending on the assay panel.

Plasma and Serum

Plasma is the preferred matrix for cfDNA/ctDNA analysis because clotting in serum releases additional DNA from blood cells, diluting the tumor fraction. Double centrifugation protocols are used to remove residual cells and platelets, ensuring high-purity cfDNA recovery for downstream sequencing or digital PCR analysis.

Urine

Urine-based liquid biopsy is valuable for urogenital malignancies such as bladder, prostate, and renal cancers. Urinary cfDNA and exosomes can carry tumor-specific mutations and methylation signatures, and collection is completely non-invasive, enabling frequent monitoring.

Cerebrospinal Fluid (CSF)

For primary brain tumors and brain metastases, CSF provides a highly enriched source of tumor-derived DNA compared with plasma, because the blood-brain barrier limits the release of ctDNA into peripheral circulation. CSF liquid biopsy is increasingly used for glioma and leptomeningeal disease assessment.

Other Body Fluids

Pleural effusion, ascites, saliva, and bone marrow aspirate may be accepted for specific indications. These matrices often contain elevated tumor fractions and are particularly useful when peripheral blood tumor shedding is low.

Testing Items

Liquid biopsy testing services cover a broad menu of molecular analytes tailored to clinical objectives:

• Single nucleotide variants (SNVs) and insertions/deletions in genes such as EGFR, KRAS, BRAF, PIK3CA, and TP53
• Gene fusions and rearrangements, including ALK, ROS1, RET, and NTRK fusions
• Copy number variations (CNVs), such as ERBB2 (HER2) amplification and MET amplification
• Microsatellite instability (MSI) status determination
• Tumor mutational burden (TMB) estimation from targeted panel sequencing
• DNA methylation markers for cancer detection and tissue-of-origin prediction
• CTC enumeration, immunophenotyping, and single-cell molecular analysis
• Extracellular vesicle (exosome) cargo analysis, including protein and RNA biomarkers
• miRNA expression profiling for diagnostic and prognostic assessment
• Known resistance mutations, for example EGFR T790M in non-small cell lung cancer

Testing Methods

Accredited third-party laboratories apply platform-appropriate methodologies matched to sensitivity requirements and clinical context:

• Next-generation sequencing (NGS): Targeted hybrid-capture or amplicon-based panels, typically 100-500 genes, with unique molecular identifiers (UMIs) to suppress sequencing errors and achieve detection limits down to 0.1% or lower variant allele frequency
• Droplet digital PCR (ddPCR): Ultra-sensitive absolute quantification of known mutations with allele fractions as low as 0.01%, ideal for MRD monitoring and targeted follow-up
• ARMS-PCR and quantitative PCR (qPCR): Rapid, cost-effective genotyping of hotspot mutations with same-day or next-day capability
• Methylation-specific PCR (MSP) and bisulfite sequencing: Detection of aberrant DNA methylation patterns used in early screening and surveillance programs
• Flow cytometry and microfluidic immunocapture: Enrichment and enumeration of CTCs based on epithelial and tumor-specific markers
• Fluorescence in situ hybridization (FISH): Fusion and amplification confirmation on isolated CTCs or matched cellular material
• Immunoassays (ELISA and chemiluminescence): Quantification of circulating protein biomarkers, including exosomal surface markers
• nanoparticle and electrochemical biosensor platforms: Emerging rapid-screening approaches under method validation

All workflows incorporate stringent quality controls, including extraction yield assessment, library complexity metrics, positive and negative controls, and synthetic spike-in reference materials traceable to established standards such as those from the World Health Organization and national reference material authorities.

Applications

Liquid biopsy testing services support decision points across the entire cancer care continuum and beyond:

• Early cancer screening and multi-cancer detection in high-risk populations using methylation and fragmentomics signatures
• Companion diagnostics to qualify patients for targeted therapies, including EGFR, ALK, ROS1, BRAF, and HER2-directed agents
• Immunotherapy eligibility assessment through MSI and TMB evaluation
• Minimal residual disease (MRD) detection after curative-intent surgery and during adjuvant therapy
• Real-time treatment response monitoring, where rising ctDNA levels often precede radiographic progression
• Resistance mechanism investigation at progression, such as detection of EGFR C797S or KRAS pathway reactivation
• Prognostic stratification based on baseline ctDNA fraction and CTC counts
• Non-invasive prenatal testing (NIPT) using maternal plasma cfDNA for fetal chromosomal aneuploidy assessment
• Transplant monitoring through donor-derived cell-free DNA quantification for organ rejection surveillance
• Pharmacodynamic evaluation in clinical trials, including ctDNA kinetics as an early efficacy endpoint

FAQ

How much blood is required for a liquid biopsy test?

Most cfDNA/ctDNA assays require two 10 mL tubes of peripheral blood. CTC analysis typically requires one 7.5-10 mL tube in a preservation tube. Exact volumes depend on the selected panel and the clinical indication.

How should samples be stored and transported?

cfDNA stabilizing tubes permit shipment at ambient temperature for up to 5-7 days, while EDTA tubes must be processed within 2-4 hours or maintained at 2-8 degrees Celsius for same-day processing. Laboratories provide detailed sample handling instructions aligned with validated stability studies.

What is the turnaround time?

Standard NGS panel results are generally delivered within 7-14 business days. ddPCR and ARMS-PCR assays for single genes can be completed within 3-5 business days. Urgent clinical scenarios can often be accommodated through expedited workflows.

What sensitivity can be expected?

NGS panels with molecular barcoding reliably detect variants at approximately 0.1-0.5% allele frequency, while ddPCR can reach 0.01-0.05% for predefined targets. Sensitivity depends on cfDNA input quantity, tumor shedding, and tumor fraction in the specimen.

Can liquid biopsy replace tissue biopsy?

Liquid biopsy complements rather than fully replaces tissue testing. It is preferred when tissue is unavailable, for serial monitoring, and for assessing heterogeneity. Tissue biopsy remains the reference standard for initial histological diagnosis and comprehensive profiling when an adequate specimen exists.

What happens if no ctDNA is detected?

A negative result does not exclude malignancy, since some tumors shed minimal DNA into the circulation. Findings are interpreted alongside imaging, clinical history, and, where available, tissue results, following clinical practice guidelines for molecular testing.